Description: Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. It focuses on areas of substantial unmet clinical need and has identified drug candidates with therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist. It currently has three wholly-owned drug programs:
Home Page: www.nyrada.com
NYR Technical Analysis
828 Pacific Highway
Gordon,
NSW
2072
Australia
Phone:
61 2 9498 3390
Officers
| Name | Title |
|---|---|
| Mr. James Bonnar | Chief Exec. Officer |
| Mr. Cameron Jones C.A. | Chief Financial Officer |
| Mr. Benjamin Evison Ph.D. | Chief Scientific Officer |
| Ms. Laura Vize | Investor Relations Mang. |
| Mr. Mark Waring B.Sc., P.M.P. | Sr. VP of US Operations |
| Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6959 |
| Price-to-Sales TTM: | 19.2561 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |